An excellent clinical response to doublet-targeted therapy with the BRAF and MEK inhibitors dabrafenib and trametinib has also been reported in an ICC patient harboring this mutation [76]. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.